Eleganoside B



Compound IDCDAMM01810
Common nameEleganoside B
IUPAC namemethyl 4a,7-dihydroxy-7-methyl-6-octoxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,5,6,7a-tetrahydrocyclopenta[c]pyran-4-carboxylate
Molecular formulaC25H42O12

Experimental data

Retention time4.43
Adduct[M+H]+
Actual mz535.276
Theoretical mz535.275
Error1.54
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score7.0847

Identifiers and class information

Inchi keyBJJIXMQSMBBRTG-FKNSVFJLNA-N
SmilesO=C(OC)C1=COC(OC2OC(CO)C(O)C(O)C2O)C3C1(O)CC(OCCCCCCCC)C3(O)C
SuperclassLipids and lipid-like molecules
ClassPrenol lipids

Pharmacokinetic properties

Number of descriptor values(#stars)2
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)18
Number of reactive functional groups (#rtvFG)3
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)534.6
Computed dipole moment(dipole)2.767
Total solvent accessible surface area (SASA)872.319
Hydrophobic component of SASA (FOSA)599.267
Hydrophilic component of SASA (FISA)236.906
Pie component of the SASA (PISA)36.147
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1623.52
Number of hydrogen bond donors (donorHB)5
Number of hydrogen bond acceptors (accptHB)16.1
Free energy of solvation of dipole (dip^2/V)0.0047157
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0412701
Globularity descriptor (glob)0.765823
Predicted polarizability in cubic angstroms (QPpolrz)47.607
Predicted hexadecane/gas partition coefficient (QPlogPC16)16.582
Predicted octanol/gas partition coefficient (QPlogPoct)31.486
Predicted water/gas partition coefficient (QPlogPw)22.886
Predicted octanol/water partition coefficient (QPlogPo/w)0.78
Predicted aqueous solubility (QPlogS)-3.505
Conformation-independent predicted aqueous solubility (CIQPlogS)-3.767
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-5.494
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)56.147
Predicted brain/blood partition coefficient (QPlogBB)-3.214
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)22.005
Predicted skin permeability, log Kp (QPlogKp)-4.03
PM3 calculated ionization potential (IP(ev))10.103
PM3 calculated electron affinity (EA(eV))0.259
Number of likely metabolic reactions (#metab)6
Prediction of binding to human serum albumin (QPlogKhsa)-0.874
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)23.948
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)182.103
Number of nitrogen and oxygen atoms (#NandO)12
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
P16109SELPP-selectinT10965SEA
P14151SELLLeukocyte adhesion molecule-1T60526SEA
P60568IL2Interleukin-2T61698SEA
P17931LGALS3Galectin-3T72038SEA
P04746AMY2APancreatic alpha-amylaseT86918SEA
P11717IGF2RInsulin-like growth factor II receptorT59550SEA
Q9UMJ8GBA1Lysosomal acid glucosylceramidaseT63243SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T10965DI0088Circulatory system disease[ICD-11: BE2Z]P16109SELP
T10965DI0381Sickle-cell disorder[ICD-11: 3A51]P16109SELP
T60526DI0037Asthma[ICD-11: CA23]P14151SELL
T60526DI0088Circulatory system disease[ICD-11: BE2Z]P14151SELL
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T86918DI0110Cystic fibrosis[ICD-11: CA25]P04746AMY2A
T86918DI0328Pancreatic malfunction[ICD-11: DC30-DC3Z]P04746AMY2A
T59550DI0146Fibrosis[ICD-11: GA14-GC01]P11717IGF2R
T59550DI0368Sarcoidosis[ICD-11: 4B20]P11717IGF2R
T63243DI0242Lysosomal disease[ICD-11: 5C56]Q9UMJ8GBA1

Copyright © 2025